Natasha Persaud

SGLT2 inhibitors and MRAs might provide complementary effects for organ protection, according to investigators.

Foot radiography and serum markers may be effective screening tools for early prevention and therapy.

Investigators reported findings from the GÖTEBORG-2, a large, population-based randomized screening trial.

The effects of combined verinurad and febuxostat treatment were independent of blood pressure.

Among other causes, dapagliflozin treatment reduced the rate of hospitalization due to cancer.

Statin use in prostate cancer is attractive given their proven cardiovascular benefits and favorable toxicity profile, according to investigators.

Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function.

Investigators examined the trajectory of nutrition parameters in patients on hemodialysis by degree of hyperparathyroidism.

Although the risks of developing a second primary cancer after radiation therapy were relatively small, they increased over time.

Coronary calcification developed with poorly controlled tertiary hyperparathyroidism and elevated iFGF23 levels after transplantation, the investigators reported.

A retrospective case-control study indicates that parathyroidectomy improves patient-level outcomes.

A round up of studies suggests it is difficult to increase serum total 25-hydroxyvitamin D levels enough to effectively lower elevated parathyroid hormone (PTH) levels in overweight patients with chronic kidney disease.

Sugar-sweetened beverages are a frequently consumed ultra-processed food group.

Investigators focused on the prognostic value of the uremic solutes asymmetric dimethylarginine, symmetric dimethylarginine, and trimethylamine-N-oxide.

Use of home dialysis and modalities other than conventional in-center hemodialysis is expected to grow.

Providers need to assess the benefit-risk profile of SGLT2 inhibitors for individual patients, and take steps to avoid unnecessary risks.

Switching from oral to intravenous calcimimetic may lower PTH levels in patients on hemodialysis with poor tolerance.

Even occasional physical activity was linked to a decreased risk for death from any cause, investigators reported.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection and may lower the risk for hyperkalemia.

The current guideline-recommended creatinine-based eGFR equation incorporates a race coefficient that may overestimate eGFR in Black adults and contribute to discordant care.

Neutrophil gelatinase-associated lipocalin (NGAL) is not only a biomarker of kidney injury but also a bone-derived factor involved in metabolism.

Avoiding even 1 metabolic syndrome component might decrease the risk for a cardiovascular event or premature death, investigators suggest.

Here’s what clinicians and patients need to know.

More severe frailty predicted a higher risk of UTIs.

Patients on hemodialysis who have secondary hyperparathyroidism experienced a 40% reduction in PTH levels over 12 months of etelcalcetide treatment, investigators reported.

Study findings indicate a correlation between iPTH and vascular calcification in patients with diabetic kidney disease.

Cardiovascular events are the leading cause of death among patients with chronic kidney disease, and metabolic acidosis in this population is underdiagnosed.

The finding is from the first population-based prevalence study of nocturnal polyuria to include both men and women, according to researchers.

Among the patients with high-risk diabetes in the trial, 21.8% had both a history of cardiovascular disease and current kidney disease.

As erectile dysfunction severity increased, serum folic acid levels decreased, an analysis found.